Immunogenicity and Neutralization of Recombinant Vaccine Candidates Expressing F and G Glycoproteins against Nipah Virus

被引:0
|
作者
Moon, Seo Young [1 ]
Flores, Rochelle A. [2 ,3 ]
Yim, Min Su [1 ]
Lim, Heeji [1 ]
Kim, Seungyeon [1 ]
Lee, Seung Yun [2 ,3 ]
Lee, Yoo-kyoung [1 ]
Kim, Jae-Ouk [4 ]
Park, Hyejin [1 ]
Bae, Seong Eun [4 ]
Ouh, In-Ohk [1 ]
Kim, Woo H. [2 ,3 ]
机构
[1] Korea Dis Control & Prevent Agcy, Natl Inst Infect Dis, Korea Natl Inst Hlth, Div Vaccine Dev Coordinat,Ctr Vaccine Res, Cheongju 28159, Chungcheongbuk, South Korea
[2] Gyeongsang Natl Univ, Coll Vet Med, Jinju 52828, Gyeongsangnam D, South Korea
[3] Gyeongsang Natl Univ, Inst Anim Med, Jinju 52828, Gyeongsangnam D, South Korea
[4] Int Vaccine Inst, Sci Unit, Mol Immunol, Seoul 08826, South Korea
关键词
Nipah virus; recombinant vaccine; antigenicity; pseudotype neutralization assay; BATS; FUSION; BANGLADESH; OUTBREAK; HENDRA; DESIGN;
D O I
10.3390/vaccines12090999
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Nipah virus (NiV), of the Paramyxoviridae family, causes highly fatal infections in humans and is associated with severe neurological and respiratory diseases. Currently, no commercial vaccine is available for human use. Here, eight structure-based mammalian-expressed recombinant proteins harboring the NiV surface proteins, fusion glycoprotein (F), and the major attachment glycoprotein (G) were produced. Specifically, prefusion NiV-F and/or NiV-G glycoproteins expressed in monomeric, multimeric (trimeric F and tetra G), or chimeric forms were evaluated for their properties as sub-unit vaccine candidates. The antigenicity of the recombinant NiV glycoproteins was evaluated in intramuscularly immunized mice, and the antibodies in serum were assessed. Predictably, all homologous immunizations exhibited immunogenicity, and neutralizing antibodies to VSV-luciferase-based pseudovirus expressing NiV-GF glycoproteins were found in all groups. Comparatively, neutralizing antibodies were highest in vaccines designed in their multimeric structures and administered as bivalent (GMYtet + GBDtet) and trivalent (Ftri + GMYtet + GBDtet). Additionally, while all adjuvants were able to elicit an immunogenic response in vaccinated groups, bivalent (GMYtet + GBDtet) and trivalent (Ftri + GMYtet + GBDtet) induced more potent neutralizing antibodies when administered with oil-in-water nano-emulsion adjuvant, AddaS03. For all experiments, the bivalent GMYtet + GBDtet was the most immunogenic vaccine candidate. Results from this study highlight the potential use of these mammalian-expressed recombinant NiV as vaccine candidates, deserving further exploration.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Recombinant Measles Virus Vaccine Expressing the Nipah Virus Glycoprotein Protects against Lethal Nipah Virus Challenge
    Yoneda, Misako
    Georges-Courbot, Marie-Claude
    Ikeda, Fusako
    Ishii, Miho
    Nagata, Noriyo
    Jacquot, Frederic
    Raoul, Herve
    Sato, Hiroki
    Kai, Chieko
    [J]. PLOS ONE, 2013, 8 (03):
  • [2] Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates
    Isaacs, Ariel
    Cheung, Stacey T. M.
    Thakur, Nazia
    Jaberolansar, Noushin
    Young, Andrew
    Modhiran, Naphak
    Bailey, Dalan
    Graham, Simon P.
    Young, Paul R.
    Chappell, Keith J.
    Watterson, Daniel
    [J]. VIRUSES-BASEL, 2021, 13 (10):
  • [3] A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins
    Carnec, Xavier
    Mateo, Mathieu
    Page, Audrey
    Reynard, Stephanie
    Hortion, Jimmy
    Picard, Caroline
    Yekwa, Elsie
    Barrot, Laura
    Barron, Stephane
    Vallve, Audrey
    Raoul, Herve
    Carbonnelle, Caroline
    Ferron, Francois
    Baize, Sylvain
    [J]. JOURNAL OF VIROLOGY, 2018, 92 (12)
  • [4] Polarized endothelial cells expressing the Nipah virus glycoproteins
    Erbar, S.
    Thiel, L.
    Diederich, S.
    Maisner, A.
    [J]. EUROPEAN JOURNAL OF CELL BIOLOGY, 2008, 87 : 30 - 30
  • [5] Assessment of the immunogenicity and protection of a Nipah virus soluble G vaccine candidate in mice and pigs
    Gao, Zihan
    Li, Tao
    Han, Jicheng
    Feng, Sheng
    Li, Letian
    Jiang, Yuhang
    Xu, Zhiqiang
    Hao, Pengfei
    Chen, Jing
    Hao, Jiayi
    Xu, Peng
    Tian, Mingyao
    Jin, Ningyi
    Huang, Weijin
    Li, Chang
    [J]. FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [6] Proteome Based Approach Defines Candidates for Designing a Multitope Vaccine against the Nipah Virus
    Soltan, Mohamed A.
    Eldeen, Muhammad Alaa
    Elbassiouny, Nada
    Mohamed, Ibrahim
    El-damasy, Dalia A.
    Fayad, Eman
    Abu Ali, Ola A.
    Raafat, Nermin
    Eid, Refaat A.
    Al-Karmalawy, Ahmed A.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (17)
  • [7] Potent immunogenicity and neutralization of recombinant adeno-associated virus expressing the glycoprotein of severe fever with thrombocytopenia virus
    Shimoyama, Toshiaki
    Oba, Mami
    Takemae, Hitoshi
    Omatsu, Tsutomu
    Tani, Hideki
    Mizutani, Tetsuya
    [J]. JOURNAL OF VETERINARY MEDICAL SCIENCE, 2024, 86 (02): : 228 - 238
  • [8] A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus
    Wendy Fonseca
    Makoto Ozawa
    Masato Hatta
    Esther Orozco
    Máximo B. Martínez
    Yoshihiro Kawaoka
    [J]. Archives of Virology, 2014, 159 : 1067 - 1077
  • [9] A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus
    Fonseca, Wendy
    Ozawa, Makoto
    Hatta, Masato
    Orozco, Esther
    Martinez, Maximo B.
    Kawaoka, Yoshihiro
    [J]. ARCHIVES OF VIROLOGY, 2014, 159 (05) : 1067 - 1077
  • [10] A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats
    McEachern, Jennifer A.
    Bingham, John
    Crameri, Gary
    Green, Diane J.
    Hancock, Tim J.
    Middleton, Deborah
    Feng, Yan-Ru
    Broder, Christopher C.
    Wang, Lin-Fa
    Bossart, Katharine N.
    [J]. VACCINE, 2008, 26 (31) : 3842 - 3852